Live Vaccines Market

Global Live Vaccines Market is valued at USD 17.48 Billion in 2020 and is expected to reach USD 27.88 Billion by 2027 with a CAGR of 6.9% over the forecast period.

 Global Live Vaccines Market Global Size, Trends, Competitive, Historical & Forecast Analysis to 2021-2027, Increasing prevalence of infectious disease, rising technological advancement in the live vaccine along with a surge in government funding to the vaccination campaigns are Major factors anticipated to drive the Global Live Vaccines Market in the forecast period.

 Scope of Global Live Vaccines Market Report:

The vaccines containing live pathogens which provide a robust immune response without causing disease are called live vaccines. The pathogenicity of the virus or bacteria is removed but it was kept alive in the vaccine. Live vaccines give long-lasting immunity in comparison to inactivated vaccines. The reverse genetics technique is used for live-attenuated vaccines like RNAi. The types of live vaccines available are chickenpox (varicella) vaccines, FluMist, Measles, mumps, and rubella (MMR) vaccines, Japanese encephalitis vaccine, Oral polio vaccine, Rotavirus vaccines, Smallpox vaccine, and yellow fever vaccine.

 Live vaccines do not need booster dose because the body will retain its immune ""memory"" of a pathogen longer as compared to kill or subunit vaccines for example hepatitis A vaccine gives protection for 20 years or more. The first successful live vaccination was carried in the 18th century by the British doctor Edward Jenner who used the cowpox virus to vaccinate children against smallpox.  Live virus vaccines are used as ""viral vectors"" for gene therapy as modified DNA is used to treat inheritable genetic disorders.

 The COVID-19 has shown a positive impact on the global live vaccines market. The live vaccine's technology is used for making vaccines against COVID -19. The development of live vaccines for COVID -19 and clinical trials positively impacted the market. There was tremendous demand for vaccines that increased during the pandemic due to the outbreak and seriousness of COVID-19.

 Global Live Vaccines Market Segmentation:

The global live vaccines market is segmented into on the basis of type, application, and region & country level. On the basis of type, the global live vaccines market is segmented into bacterial vaccines and viral vaccines. On the basis of application, the market is segmented into hospitals, clinics, research institutes, and others.

 By Type:

• Bacterial
• Viral

By Application:

• Hospitals
• Clinics
• Research Institutes
• Others

The regions covered in the global live vaccines market report are North America, Europe, Asia-Pacific, Latin America, and the Rest of the World. On the basis of country level, the market of global live vaccines is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East, GCC (UAE, Egypt, Saudi Arabia), Africa, etc.

 Key Players for Global Live Vaccines Market Report:

Some of the key players for the global live vaccines market are:

• GlaxoSmithKline Merck Pfizer
• Astellas Pharma
• Johnson and Johnson
• CSL, Sanofi
• Serum Institute of India
• others

News:

IIL launched goat pox vaccine

20th December 2021; Indian Immunologicals Limited (IIL) had announced the launch of the goat pox vaccine. The vaccine was a live attenuated vaccine, and the primary vaccination was done at 3 months of age and revaccination annually with a dose rate of 1ml. Smallpox was highly contagious and spreads through contact, aerosol and it was severe in young-old, and lactating animals.

 Increasing prevalence of infectious disease, rising technological advancement in the live vaccine, and Growing government funding to the vaccination campaigns are major factors anticipated to drive the Global Live Vaccines Market

One of the major factors driving the growth of the live vaccines market is the increasing prevalence of infectious diseases. Live vaccines provide long-lasting immunity against infections. These vaccines contain version live bacteria or virus thus the immune system recognizes these as a natural infection and an immune response was developed which is long-lasting. For instance, according to the World Health Organization (WHO), as of 17th December 2021, there are 271,963,258 confirmed cases of COVID-19, globally. In addition to that, another factor driving the growth of the live vaccines market is a surge in technological advancements for vaccines. For instance, on 14th December 2020, the COVI-VAC vaccine was developed by the serum institute of India. This vaccine is a single-dose intranasal, live vaccine against SARS-CoV-2, that was shown to be safe and efficacious in preclinical animal studies. COVI-VAC is a safe, live attenuated version of SARS-CoV-2 that may induce a more robust immune response and long-lasting cellular immunity against SARS-CoV-2 compared to other vaccines against the virus.

 Furthermore, growing government funding to vaccination campaigns also drives the global live vaccine market. The government is always in a mindset to stop the spread of the virus and vaccinations is one of the easiest method and preventive measure to stop the spread of the disease. For example, on 6th April 2021, for increasing the covid-19 vaccine uptake CDC (Centers for Disease Control and Prevention) had granted funding to support local efforts. The awards are part of $3 billion in funding that CDC has approved to 64 jurisdictions to support broad-based vaccine distribution, contact, and administration efforts. Moreover, increasing awareness about vaccines also drives growth in the market. However, the vaccines need to be kept cool, thus the storage requirement of live vaccines hampering the growth of the market. In spite of that, research and development in live vaccines are providing opportunities in the global live vaccines market.

 North America has Highest Revenue Share for the Global Live Vaccines Market

North America has the highest revenue share for the global live vaccines market due to increased adoption of live vaccines, and rising research and development in vaccines followed by the approval of live vaccines. In the U.S increased adoption of live vaccines such as the Measles vaccine, Polio vaccine, Rotavirus. These vaccinations led to the eradication of diseases thus, increasing the adoption of live vaccines boosting the market growth. In addition to that, increased research and development activities and approvals for live vaccines also fuel market growth in this region. For instance, as per the news published on 24th September 2019, FDA had approved primary live, non-replicating vaccines to avoid smallpox and monkeypox.

 The Asia Pacific is the second-largest market for the global live vaccines market due to the increased number of infectious diseases, higher rate of population, rising initiatives by government bodies to control the disease rate in the region. For instance, as of 17th December 2021 according to WHO (World Health Organization), there have been 34,726,049 confirmed cases of COVID-19. The emergence of variants and research driving the growth of live vaccines in the Asia Pacific region. In addition to that, rising initiatives by the government to control the disease are also fueling market growth. For instance, on 18th December 2021, World Health Organization (WHO) permitted Covovax for crisis use for COVID-19 patients. Covovax is a form of live vaccine thus it is adding growth to the global live vaccines market in the Asia Pacific region.

 On Special Requirement Live Vaccines Market Report is also available for below Regions and Country:

North America

•  U.S.
• Canada

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Switzerland
• Belgium
• Rest of Europe

Asia-Pacific

• South Korea
• Japan
• China
• India
• Australia
• Philippines
• Singapore
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Colombia
• Brazil
• Argentina
• Peru
• Rest of South America

Middle East and Africa 

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA 

Report Analysis	Details
Historical data	2015 - 2020
Forecast Period	2021 - 2027
Market Size in 2020:	USD 17.48 Billion
Base year considered	2020
Forecast Period CAGR %:	6.9%
Market Size Expected in 2027:	USD 27.88 Billion
Tables, Charts & Figures:	175
Pages	200
Live Vaccines Manufacturers	GlaxoSmithKline Merck Pfizer, Astellas Pharma, Johnson and Johnson, CSL, Sanofi, Serum Institute of India, others
Segments Covered	By Type, By Application
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Key Benefits in Global Live Vaccines Market Report:

• Global Live Vaccines report covers in-depth historical and forecasts analysis.
• Global Live Vaccines research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.
• Global Live Vaccines report helps to identify opportunities in the marketplace.
• Global Live Vaccines report covers extensive analysis of emerging trends and competitive landscape.